Skip to main content
Premium Trial:

Request an Annual Quote

Genomica Completes $13.6M Private Financing

Premium

BOULDER, Colo.--Genomica, which describes itself as a pharmacogenomics software company, completed a $13.6 million private placement of series B convertible preferred stock this month. Punk Ziegel managed the placement. Investors included the Kaufman Fund, Anvers L.P., Falcon Technology Partners, Invesco Global Health Sciences Fund, Arch Venture Partners, and Boulder Ventures. Skip Klein, a healthcare analyst with Kaufman, said of Genomica's Discovery Manager software, "Users I've spoken to praise the product for its industrial- strength quality and ease of use. It appears that Genomica has the chance to be the Bloomberg or the Microsoft of genomics." Genomica was established in 1996 by Thomas Marr to commercialize tools he and his team developed at Cold Spring Harbor Laboratory in New York.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.